3rd CNS Anticancer Drug Discovery and Development Conference

We are pleased to announce that the 3rd CNS Anticancer Drug Discovery and Development Conference (CADDDC) will be held November 14 - 15, 2018 just prior to the SNO Annual Meeting in New Orleans. The Scientific Program Committee is developing a world-class program that will provide an educational venue for scientists, clinicians, and regulatory decision-makers to better understand the special requirements for effective anticancer therapies for the treatment of primary infiltrative gliomas, medulloblastoma, and metastatic tumors to the CNS.  The Conference will provide a setting to facilitate discussion of the range of issues that have impacted on the failure to develop unique drugs for CNS cancers as well as innovative approaches being applied to brain tumor chemotherapy.  Through this educational and research-oriented conference the goals are to create a dialogue amongst attendees and their collaborators to enhance drug development for primary gliomas, medulloblastoma, and secondary metastatic CNS tumors and, thereby, improve patient outcomes.

Following the first CADDDC in 2014, participants generated a White Paper that was published as a supplement to the journal Neuro-Oncology (https://academic.oup.com/neuro-oncology/article/17/suppl_6/vi1/1087922).  The second CADDDS in 2016 led to a publication in CNS Oncology that summarized the Conference (https://www.futuremedicine.com/doi/abs/10.2217/cns-2017-0014).  For those contemplating attending this year's CNS Anticancer Drug Discovery and Development Conference, reading these two documents will help you appreciate the breadth and value of these conferences. Abstracts are now being accepted; it is expected that 12-14 abstracts will be accepted for platform presentation.

Register Now!
Government/Academia: early bird $295; after 9/7 $345
Industry: early bird $395; after 9/7 $445

At this time, 20 speakers have agreed to present at the Conference.  A preliminary list of proposed sessions (subject to change), as well as the list of confirmed speakers to date is below.

Planned Sessions
  • Pharmacokinetics and the blood-brain barrier 
  • Biophysical modeling of brain tumors to guide drug discovery and development
  • Novel targets, approaches and paradigms
  • Drug discovery efforts and accomplishments 
  • The societal, regulatory, and pharmaceutical/biotech conundrum

Confirmed Speakers to Date
  • Suzy Baker (St. Jude Children's Research Hospital
  • Joseph F. Costello (UCSF Medical School)
  • Ken Dill (Stony Brook School of Medicine)
  • William Elmquist (University of Minnesota)
  • Stewart Fisher (C4 Therapeutics)
  • Chang Gong (Johns Hopkins University, Popel Lab)
  • Gary Gordon (AbbVie)
  • Victor Levin (University of Texas MD Anderson Cancer Center; UCSF Medical School; Kaiser Permanente)
  • Jing Li (Karmanos Cancer Institute)
  • Young-Choon Moon (PTC Therapeutics)
  • David Odde (University of Minnesota)
  • Kurt Pike (AstraZeneca)
  • Jeremy Rich (University of California, San Diego)
  • Steve Rosenfeld (Mayo Clinic)
  • Jann Sarkaria (Mayo Clinic)
  • Dhaval Shah (University of Buffalo)
  • Ali Shilatifard (Northwestern University)
  • Quentin Smith (Texas Tech University School of Pharmacy)
  • Peter Tonge (Stony Brook School of Medicine)
  • Forest White (MIT)

Scientific Program Committee
Victor A. Levin, MD, Chair
Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center
Department of Neurosurgery, UCSF Medical School

James M. Gallo, PharmD, PhD
Department of Pharmaceutical Sciences
Albany College of Pharmacy and Health Sciences

David J. Odde, PhD
Department of Biomedical Engineering
University of Minnesota

Russell C. Petter, PhD
Founder and Chief Scientific Officer
Arrakis Therapeutics

Zoran Rankovic, PhD
CBT Chemistry Centers
St Jude Children's Research Hospital

Jeremy N. Rich, MD
Department of Medicine
UCSD School of Medicine

Peter J. Tonge, PhD
Departments of Chemistry and Radiology
Stony Brook School of Medicine